Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The clinical activity of rituximab, a chimeric monoclonal antibody which binds to the CD20 antigen, was evaluated as a single first-line therapy for patients with follicular non-Hodgkin lymphoma (NHL). Fifty patients with follicular CD20(+) NHL and a low tumor burden were analyzed for clinical and molecular responses. They received 4 weekly infusions of rituximab at a dose of 375 mg/m(2). The response rate a month after treatment (day 50) was 36 of 49 (73%), with 10 patients in complete remission, 3 patients in complete remission/unconfirmed, and 23 patients in partial remission. Ten patients had stable disease, and the disease progressed in 3 patients. One of 13 (8%) patients in complete remission, 9 of 23 (39%) patients in partial remission, and 5 of 10 (50%) patients with stable disease exhibited disease progression during the first year. Within the study population, 32 patients were initially informative for polymerase chain reaction (PCR) data on bcl-2-J(H) rearrangement. On day 50, 17 of 30 patients (57%) were negative for bcl-2-J(H) rearrangement in peripheral blood, and 9 of 29 (31%) were negative in bone marrow; a significant association was observed between molecular and clinical responses (P <.0001). At month 12, 16 of 26 patients (62%) were PCR negative in peripheral blood. These results indicate that early molecular responses can be sustained for up to 12 months and that this response is highly correlated with progression-free survival. Rituximab has a high clinical activity and a low toxicity and induces a high complete molecular response rate in patients with follicular lymphoma and a low tumor burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I., & Solal-Céligny, P. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1110 · Cited by 647
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Press, O. W., Appelbaum, F., Martin, P. J., Matthews, D. C., Bernstein, I. D., Eary, J. F., Nelp, W. B., Gooley, T., Glenn, S., Porter, B., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92225-3 · Cited by 428
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1974 · Cited by 396
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., & Thomas, E. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
Davis, T. A., White, C. A., Grillo-López, A. J., Velasquez, W. S., Link, B. K., Maloney, D. G., Dillman, R. O., Williams, M. E., Mohrbacher, A., Weaver, R. L., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1851 · Cited by 290
Liu, S. Y., Eary, J. F., Petersdorf, S. H., Martin, P. J., Maloney, D. G., Appelbaum, F. R., Matthews, D. C., Bush, S. A., Durack, L. D., Fisher, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3270 · Cited by 286
Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome
Warzocha, K., Ribeiro, P., Bienvenu, J., Roy, P., Charlot, C., Rigal, D., Coiffier, B., & Salles, G. (1998) · Blood · doi:10.1182/blood.v91.10.3574 · Cited by 272
Byrd, J. C., Waselenko, J. K., Maneatis, T. J., Murphy, T., Ward, F. T., Monahan, B. P., Sipe, M. A., Donegan, S., & White, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.791 · Cited by 264
Amlot, P., Stone, M., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., & Ghetie, V (1993) · Blood · doi:10.1182/blood.v82.9.2624.2624 · Cited by 235
Brown, S., Miller, R., Horning, S., Czerwinski, D., Hart, S., McElderry, R., Basham, T., Warnke, R., Merigan, T., & Levy, R. (1989) · Blood · doi:10.1182/blood.v73.3.651.651 · Cited by 175
The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas
López‐Guillermo, A., Cabanillas, F., McLaughlin, P. J., Smith, T., Hagemeister, F. B., Rodriguez, M. A., Romaguera, J. E., Younes, A., Sarris, A. H., Preti, H. A., et al. (1998) · Blood · doi:10.1182/blood.v91.8.2955.2955_2955_2960 · Cited by 162
Tobinai, K., Kobayashi, Y., Narabayashi, M., Ogura, M., Kagami, Y., MORISHIMA, Y., Ohtsu, T., Igarashi, T., Sasaki, Y., Kinoshita, T., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008265313133 · Cited by 151
Stone, M., Sausville, E., Fay, J. W. J., Headlee, D. J., Collins, R., Figg, W. D., Stetler-Stevenson, M. A., Jain, V. K., Jaffe, E., Solomon, D., et al. (1996) · Blood · doi:10.1182/blood.v88.4.1188.bloodjournal8841188 · Cited by 139
Treatment approaches to the low-grade lymphomas
Horning, S. J. (1994) · Blood · doi:10.1182/blood.v83.4.881.881 · Cited by 108
Maloney, D. G., Brown, S. L., Czerwinski, D. K., Liles, T. M., Hart, S. M., Miller, R., & Levy, R. (1992) · Blood · doi:10.1182/blood.v80.6.1502.1502 · Cited by 78
Finke, J., Slanina, J., Lange, W., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1668 · Cited by 78
Cited by
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Self-citationDave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041869 · Cited by 1,418
Follicular lymphoma international prognostic index
Solal-Celigny, P. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0036-3 · Cited by 1,339
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Metadata
- Authors
- Colombat, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-01-01
- Volume
- 97
- Issue
- 1
- Pages
- 101-106
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2167635913
- Cited by
- 524
- References
- 26
- FWCI
- 30.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.